Apollo Endosurgery Intrinsic Value Calculation – Is Apollo Endosurgery [APEN] Missing a Long-Term Opportunity at $9.92 in 2023?
March 12, 2023
Trending News ☀️
Given the current stock price of Apollo Endosurgery ($NASDAQ:APEN) Inc. APEN, which is trading at $9.92, down -0.10% from its prior close of $9.93, many investors might be asking if it is a long-term opportunity that has been overlooked. The company is best known for its products and services related to endoscopy, robotics, and surgical devices. Apollo Endosurgery has seen an increase in revenue due to the rising demand for its products and services in the medical industry. The current stock price of Apollo Endosurgery Inc. is a great opportunity for long-term investors as the company is well positioned to benefit from the growth of the endoscopy, robotics, and surgical markets in the near future.
In addition, Apollo Endosurgery has been able to consistently grow its profits over the years and is well-positioned to capitalize on the increased demand for its products and services from healthcare providers and patients alike. The current stock price of Apollo Endosurgery Inc. provides investors with a great opportunity for long-term investments. The company’s robust revenue growth and strong financial performance demonstrate that it will continue to remain profitable in the future. Furthermore, investors will benefit from the potential for future growth as the company continues to expand its product offerings and market share. In conclusion, at the current stock price of $9.92, Apollo Endosurgery Inc. is providing a great opportunity for long-term investors who are looking to capitalize on the growth of the endoscopy, robotics, and surgical markets. The company’s strong financial performance and consistent revenue growth indicate that it is well-positioned to remain profitable in the near future and will continue to provide investors with an ideal long-term opportunity.
On Friday, APOLLO ENDOSURGERY stock opened at $9.9 and closed at $9.9, down by 0.1% from its last closing price of 9.9. However, this could be indicative of a long-term opportunity that is being missed out by investors. Although the stock has not seen any major changes lately, it may be worth considering to invest in the company as its stock may be undervalued and potentially have more room to grow in the long-term. Live Quote…
About the Company
Below shows the total revenue, net income and net margin for Apollo Endosurgery. More…
|Total Revenues||Net Income||Net Margin|
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Apollo Endosurgery. More…
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Apollo Endosurgery. More…
|Total Assets||Total Liabilities||Book Value Per Share|
Key Ratios Snapshot
Some of the financial key ratios for Apollo Endosurgery are shown below. More…
|3Y Rev Growth||3Y Operating Profit Growth||Operating Margin|
Analysis – Apollo Endosurgery Intrinsic Value Calculation
At GoodWhale, we have analyzed the financials of APOLLO ENDOSURGERY and determined its fair value to be around $4.9. This value was calculated using our proprietary Valuation Line model. However, the current price of APOLLO ENDOSURGERY’s share is $9.9, making it overvalued by a staggering 102.4%. This presents a great opportunity for investors to buy the stock at a discounted rate. More…
Apollo Endosurgery Inc, a company that manufactures medical devices, competes with ClearPoint Neuro Inc, Heart Tronics Inc, and SI-BONE Inc. Each company manufactures devices that are used for different purposes.
– ClearPoint Neuro Inc ($NASDAQ:CLPT)
ClearPoint Neuro Inc. is a medical device company that designs, develops, and markets products to treat neurological disorders. The company’s products are used in the treatment of Parkinson’s disease, Essential Tremor, and Obsessive Compulsive Disorder. ClearPoint Neuro Inc. has a market cap of $230.43 million and a return on equity of -35.67%. The company’s products are used in the treatment of neurological disorders. ClearPoint Neuro Inc. designs, develops, and markets products to treat neurological disorders.
– Heart Tronics Inc ($OTCPK:HRTT)
Heart Tronics Inc is a company that specializes in medical devices and equipment. The company has a market capitalization of 15.68k as of 2022 and a return on equity of 110.55%. The company’s products include cardiac monitors, defibrillators, and pacemakers. The company’s products are used in the diagnosis and treatment of cardiac conditions.
– SI-BONE Inc ($NASDAQ:SIBN)
SI-BONE Inc is a medical device company that develops, manufactures, and markets minimally invasive surgical implants for the treatment of patients with disorders of the sacroiliac joint. As of 2022, the company had a market capitalization of $627.78 million and a return on equity of -33.15%. The company’s products are used by orthopedic surgeons to treat conditions such as sacroiliac joint dysfunction, sacral insufficiency fractures, and degenerative sacroiliitis.
Apollo Endosurgery Inc. (APEN) is an innovative medical device company with a focus on providing minimally invasive endoscopic surgical products and services. With a current share price of $9.92, the company presents an attractive long-term investment opportunity for investors. The company has a diverse portfolio of products, ranging from single-use devices, such as the OverStitch Sx Endoscopic Suturing System, to multi-purpose tools, including the Linear Cutter Endoscopic Stapler System. Apollo Endosurgery has secured FDA clearance for many of its products, and its commitment to developing innovative products has resulted in positive news coverage. The company’s strong balance sheet and experienced management team further support the long-term potential of the stock.
In addition, APEN’s expanding foreign presence allows it to capitalize on growth opportunities in the international market. Based on the current market trends and prospects for continued growth, Apollo Endosurgery Inc. appears to be a solid investment for investors with a long-term outlook.
Leave a Comment